Clinical Trial Update: 28-day Repeat Dose and Drug Interaction Study With Orvepitant (GW823296) [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update reports results from a 28-day repeat-dose and drug interaction study of Orvepitant (GW823296) in depressive disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Depressive Disorder

Drugs mentioned

• Orvepitant (Orvepitant)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Depressive Disorder | Phase 1 | Status: COMPLETED